查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1873163

全球生物製藥安全性檢測市場

Biologics Safety Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球生物製藥安全檢測市場預計2030年將達到130億美元

2024年全球生物製藥安全檢測市場規模估計為66億美元，預計到2030年將達到130億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為11.8%。本報告分析的細分市場之一—殘留宿主細胞蛋白和DNA檢測，預計將以12.9%的複合年成長率成長，並在分析期結束時達到58億美元。黴漿菌檢測細分市場預計在分析期間將以10.1%的複合年成長率成長。

美國市場規模估計為18億美元，而中國市場預計將以11.1%的複合年成長率成長。

預計2024年，美國生物製藥安全檢測市場規模將達18億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到20億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到11.1%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，這兩個國家的複合年成長率將分別達到10.4%和9.8%。在歐洲，德國預計將以約8.6%的複合年成長率成長。

全球生技藥品安全檢測市場－主要市場趨勢與促進因素概述

為什麼生技藥品安全性測試是生物製藥研發的基石

生物製劑安全測試是生物製藥研發的基石，旨在確保疫苗、單株抗體、基因療法和細胞療法等複雜生物製藥的安全性。與傳統化學藥物不同，生物製劑生物來源，其複雜的結構和潛在的免疫反應使其面臨獨特的挑戰。安全性測試包括全面的檢測，以檢測可能損害產品安全性的污染物，例如病毒、黴漿菌和內毒素。此外，宿主細胞蛋白 (HCP) 污染的檢測也至關重要，因為生產細胞株中殘留的蛋白質可能引發有害的免疫反應。這些嚴格的測試旨在滿足美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構制定的高安全標準。生物製藥安全性測試對於保護公眾健康、確保生物製藥的安全性和有效性至關重要。

法規要求如何影響生物製藥安全性測試？

監管要求是推動生物製藥安全檢測發展的根本動力，它規定了確保生物製藥符合嚴格安全和品質標準的方法和技術。美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和世界衛生組織 (WHO) 等國際組織已製定了全面的指南，明確規定了所需的安全檢測、檢測頻率和可接受的污染閾值。對於希望將生物製藥推向市場的公司而言，遵守這些法規至關重要；不遵守法規可能導致嚴重的延誤、產品召回，甚至被完全拒收。隨著生物製藥的複雜性日益增加，監管標準也日趨嚴格，推動了次世代定序(NGS) 和質譜等先進檢測技術的應用。這些方法具有更高的靈敏度和特異性，能夠偵測到微量污染物。不斷變化的監管環境持續促進生物製藥安全檢測的創新，確保該行業始終能夠應對不斷湧現的安全挑戰。

哪些創新正在改變生物製藥安全性測試？

近年來，技術進步重塑了生物製藥安全性檢測領域，顯著提高了檢測程序的準確性、靈敏度和效率。高通量篩檢(HTS) 技術是其中最具影響力的進步之一，它能夠快速檢測大量樣本，從而縮短生物製藥的研發週期。同時，基於細胞的檢測方法也在加速應用，與傳統的體外方法相比，這些方法能夠提供更具相關性的生理數據。這些檢測方法對於在研發早期階段檢測潛在的免疫抗原性和細胞毒性至關重要，能夠更深入地了解生物製藥的安全性。人工智慧 (AI) 和機器學習也發揮著重要作用，它們增強了數據分析能力，能夠更準確地識別模式和預測結果。此外，新型生物感測器和微流體平台的出現，促進了即時現場檢測，並實現了對生物製藥生產過程中的持續監測。這些技術進步不僅提高了安全性檢測的可靠性，還有助於提高工作流程效率並降低整體成本，從而使生物製藥的研發過程更有效率。

哪些因素推動了生物製藥安全檢測市場的快速成長？

生物製藥安全檢測市場的成長受多種因素驅動。其中一個關鍵促進因素是生物製藥產業本身的快速發展，這得益於對包括個人化醫療和免疫療法最先進治療的需求不斷成長。隨著生物製藥開發平臺的不斷擴展，對全面安全檢測的需求日益增加，促使生物製藥公司加強對先進檢測技術的投資。此外，生物相似藥（與已獲核准產品高度相似的生物製劑）的日益普及，也使得人們更加關注安全檢測，以確保這些產品符合等效性和安全標準。監管機構透過實施更嚴格的安全檢測要求，要求進行更頻繁、更嚴謹的檢測，在推動市場成長方面也發揮關鍵作用。將自動化、人工智慧和次世代定序引入安全檢測通訊協定，透過提高效率和準確性，進一步促進了市場擴張。最後，生物製藥產業的全球化正在推動各地區安全標準的協調統一，從而增加了對標準化和可靠檢測方法的需求。這些因素共同推動了生物製藥安全檢測市場的強勁成長。

部分：

細分市場（服務、試劑盒和試劑、設備）、檢測類型（殘留宿主細胞蛋白和DNA檢測、黴漿菌檢測、無菌檢測、內毒素檢測、其他檢測）、應用領域（單株抗體生產、疫苗生產、血液和血液製品生產、細胞和基因治療產品生產、其他應用）

受訪公司範例

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

與典型的LLM或產業專用的SLM方法不同，Global Industry Analysts建立了一個由世界各地領域專家精心策劃的內容庫，包括影片轉錄、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

我們最新發布的報告納入了關稅對區域市場的影響，正如全球產業分析師預測的那樣，關稅將改變企業的競爭地位，而企業的競爭地位將取決於其總部所在地、製造地以及進出口（成品和OEM產品）。這種複雜多變的市場現實將透過微觀和宏觀市場動態影響競爭對手，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP10720

Global Biologics Safety Testing Market to Reach US$13.0 Billion by 2030

The global market for Biologics Safety Testing estimated at US$6.6 Billion in the year 2024, is expected to reach US$13.0 Billion by 2030, growing at a CAGR of 11.8% over the analysis period 2024-2030. Residual Host-Cell Proteins & DNA Detection Tests, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Mycoplasma Tests segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 11.1% CAGR

The Biologics Safety Testing market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.4% and 9.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR.

Global Biologics Safety Testing Market - Key Trends and Drivers Summarized

What Makes Biologics Safety Testing a Pillar of Biopharmaceutical Development?

Biologics safety testing stands as a fundamental pillar in the development of biopharmaceuticals, ensuring that complex biological products, including vaccines, monoclonal antibodies, gene therapies, and cell-based treatments, are safe for patient use. Unlike traditional chemical drugs, biologics are derived from living organisms, presenting unique challenges due to their intricate structures and potential to trigger immune responses. Safety testing involves a comprehensive array of assays aimed at detecting contaminants such as viruses, mycoplasma, and endotoxins that could compromise the product's safety. Additionally, testing for host cell protein (HCP) contamination is crucial since residual proteins from production cell lines can provoke adverse immune reactions. The stringent nature of these tests is driven by the need to meet the high safety standards set by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The critical importance of biologics safety testing lies in its ability to safeguard public health and ensure that biologics are both safe and effective.

How Do Regulatory Requirements Influence Biologics Safety Testing?

Regulatory requirements are a driving force behind the evolution of biologics safety testing, dictating the methods and technologies used to ensure that biologic products meet stringent safety and quality standards. International bodies such as the FDA, EMA, and World Health Organization (WHO) have established comprehensive guidelines that specify the necessary safety tests, the frequency of these tests, and acceptable contamination thresholds. Compliance with these regulations is essential for companies aiming to bring biologics to market, as non-compliance can lead to significant delays, recalls, or outright rejection of a product. Over time, as biologics have become more complex, regulatory standards have become more rigorous, pushing the adoption of advanced testing techniques like next-generation sequencing (NGS) and mass spectrometry. These methods offer heightened sensitivity and specificity, capable of detecting even minute levels of contaminants. The constantly evolving regulatory landscape continues to drive innovation in biologics safety testing, ensuring that the industry remains equipped to address emerging safety challenges.

Which Technological Innovations Are Transforming Biologics Safety Testing?

Recent technological innovations are reshaping the field of biologics safety testing, leading to significant improvements in the accuracy, sensitivity, and efficiency of testing procedures. High-throughput screening (HTS) technologies represent one of the most impactful advancements, enabling the rapid testing of large sample volumes, thus accelerating the development timeline for biologics. Concurrently, the adoption of cell-based assays has gained momentum, providing more relevant physiological data compared to traditional in vitro methods. These assays are crucial for detecting potential immunogenicity and cytotoxicity early in the development process, offering deeper insights into the safety profile of biologics. Artificial intelligence (AI) and machine learning are also making their mark by enhancing data analysis capabilities, allowing for more precise identification of patterns and prediction of outcomes. Moreover, the advent of novel biosensors and microfluidic platforms has facilitated real-time, on-site testing, enabling continuous monitoring of biologics during production. These technological advancements are not only enhancing the reliability of safety testing but also streamlining workflows and reducing overall costs, making the biologics development process more efficient and effective.

What’s Driving the Rapid Growth in the Biologics Safety Testing Market?

The growth in the biologics safety testing market is driven by several factors. A primary driver is the rapid growth of the biologics sector itself, fueled by the increasing demand for cutting-edge therapies, including personalized medicine and immunotherapies. As the pipeline of biologics continues to expand, there is a heightened need for comprehensive safety testing, prompting biopharmaceutical companies to invest heavily in advanced testing technologies. Additionally, the rising prevalence of biosimilars-biologics that are highly similar to already approved products-has intensified the focus on safety testing to ensure these products meet equivalency and safety standards. Regulatory agencies have also played a significant role in this market growth by imposing more stringent safety testing requirements, necessitating more frequent and rigorous testing. The incorporation of automation, artificial intelligence, and next-generation sequencing into safety testing protocols has further propelled market expansion by enhancing efficiency and accuracy. Lastly, the globalization of the biopharmaceutical industry has led to increased efforts to harmonize safety standards across different regions, driving demand for standardized and reliable testing methods. These factors collectively are fueling the robust growth of the biologics safety testing market.

SCOPE OF STUDY:

The report analyzes the Biologics Safety Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Services, Kits & Reagents, Instruments); Test Type (Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests, Other Tests); Application (Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 13 Featured) -

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Biologics Safety Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Stringency in Regulatory Requirements Propels Market Growth for Biologics Safety Testing
    • Advancements in Analytical Technologies Strengthen the Business Case for Enhanced Safety Testing
    • Surging Demand for Biologics and Biosimilars Generates Accelerated Need for Comprehensive Safety Testing
    • Technological Innovations in Rapid Testing Methods Drive Adoption Across Biopharma Companies
    • Regulatory Compliance Standards Throw the Spotlight on the Critical Importance of Safety Testing in Biologics Development
    • Expanding Biologics Pipeline Spurs Growth in the Safety Testing Market
    • Rising Incidence of Biologic Contamination Issues Sustains Demand for Rigorous Testing Protocols
    • Increasing Focus on Patient Safety and Product Quality Drives Adoption of Advanced Biologics Safety Testing Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Monoclonal Antibody Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Vaccine Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Blood & Blood Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Cellular & Gene Therapy Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Mycoplasma Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Sterility Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Endotoxin Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Biologics Safety Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • JAPAN
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • CHINA
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • EUROPE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • GERMANY
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of World 15-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2015, 2025 & 2030

IV. COMPETITION